ropsacitinib

Ropsacitinib (PF-06826647) is a selective and orally administered small molecule inhibitor of tyrosine kinase 2 (TYK2), a member of the Janus kinase (JAK) family. It is being developed primarily for the treatment of moderate-to-severe plaque psoriasis. The drug acts by inhibiting TYK2-dependent signaling pathways involved in pro-inflammatory cytokine signaling such as IFNα, IL-12, and IL-23. Clinical studies have shown that PF-06826647 demonstrates significant efficacy in reducing psoriasis severity compared to placebo and has been generally well tolerated over periods up to 40 weeks[1][3][4][5]. Ropsacitinib was discovered and developed by Pfizer[5].

Other names

ropsacitinibPF-06826647PF06826647PF 06826647Tyk2-IN-8Tyk-2-IN-8Tyk 2-IN-8